Merck Tries To Acquire Cubist Pharmaceuticals For More Than $7B
International Business Times
Published Dec 06, 2014 06:51AM ET
Updated Dec 06, 2014 07:30AM ET
Merck Tries To Acquire Cubist Pharmaceuticals For More Than $7B
By Sneha Shankar -
Merck & Co. is near closing a deal to buy Cubist Pharmaceuticals Inc (NASDAQ:CBST), an antibiotics-maker, in a deal worth more than $7 billion, reports said Friday citing company officials. The deal, which is expected to be announced next week, comes as a part of Merck’s strategy to buy mid-size drug makers to expand its business.
New Jersey-based Merck would pay nearly $100 per share for Cubist, valuing the company at nearly $7.5 billion, about 34 percent more than Cubist’s closing price on Friday, The Wall Street Journal reported. Massachusetts-based Cubist makes drugs that fight infectious diseases and manufactures its flagship drug Cubicin, which recorded sales of $967 million in 2013. Although antibiotics are not considered to be a lucrative option for the drug industry, analysts expect that new versions could earn high profits for the companies.
The deal would also allow Merck to access Cubist’s medicines, which are mostly used in hospitals, according to CNBC.
Cusbist’s focus area for its products is on manufacturing drugs that could address “significant unmet medical needs,” including diseases that lead to global pandemics, according to the New York Times. The company reported sales of $309 million in the third quarter of this year, showing an increase of 16 percent over the last year for the same quarter. Last year, Cubist had also acquired smaller businesses like Trius and Optimer, further expanding its foothold on antibiotics segment, CNBC reported.
Merck, which is the second largest American drugmaker after Pfizer (NYSE:PFE), has a market value of over $174 billion and reported sales worth $10.56 billion in the third quarter of 2014, the Times reported. While the company’s vaccine for cervical cancer faces increased competition, its diabetes drug, the largest line for the company, continues to clock high sales.
In October, Merck also closed a deal to sell its consumer business to Bayer for $14.2 billion. In June, Merck bought Idenix Pharmaceuticals, which makes drugs for treating human viral diseases, for $3.85 billion.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.